Novel approach to reduce postsurgical adhesions to a minimum: Administration of losartan plus atorvastatin intraperitoneally

Abstract Background Intraperitoneal adhesions are the most important cause of intestinal obstruction, pelvic pain, and female infertility. Materials and methods Losartan (1, 5, and 10 mg/kg), atorvastatin (1, 20, and 30 mg/kg), losartan (10 mg/kg) plus atorvastatin (20 mg/kg), and sodium hyaluronate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of surgical research 2013-05, Vol.181 (1), p.91-98
Hauptverfasser: Dinarvand, Peyman, MD, Farhadian, Shirin, DMD, Seyedjafari, Ehsan, PhD, Shafiee, Abbas, MSc, Jalali, Arash, PhD, Sanaei-rad, Parisa, DMD, Dinarvand, Babak, MD, Soleimani, Masoud, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Intraperitoneal adhesions are the most important cause of intestinal obstruction, pelvic pain, and female infertility. Materials and methods Losartan (1, 5, and 10 mg/kg), atorvastatin (1, 20, and 30 mg/kg), losartan (10 mg/kg) plus atorvastatin (20 mg/kg), and sodium hyaluronate/carboxymethylcellulose (HA/CMC) were administered intraperitoneally in 90 male NMRI mice. After 7 d, the grade of adhesions was scored by two scaling methods and the concentrations of TGF-β1, tPA, and PAI-1 were also evaluated. Results Simultaneous intraperitoneal administration of losartan and atorvastatin led to a much higher reduction of adhesions compared with that in the HA/CMC group ( P < 0.05). When losartan plus atorvastatin was administered, significant changes in the serum concentration and mRNA expression, including the increase of tPA and the decrease of TGF-β1 and PAI-1, were observed compared with those in other groups. Conclusions Our findings suggest that the simultaneous application of losartan and atorvastatin leads to an enhanced reduction in adhesion bands more than that of HA/CMC treatment, compared with the control group, possibly through balancing the expression of TGF-β1, tPA, and PAI-1.
ISSN:0022-4804
1095-8673
DOI:10.1016/j.jss.2012.05.035